继发于骨髓增殖性肿瘤的白血病
继发于骨髓增殖性肿瘤(MPN)的继发性急性髓系白血病(AML)具有独特的细胞遗传学和分子特征,不同于新发AML。由于高危细胞遗传学和分子特征频率高,恶性克隆常对传统AML化疗药物不敏感。异基因干细胞移植是唯一显示长期获益的治疗方式,但患者诊断时高龄且常合并症多,常无法进行,且即使移植复发率仍高。本文综述MPN白血病转化的已知危险因素、分子特征进展、当前治疗策略及新兴治疗选择。
要点
- MPN继发AML具有独特的细胞遗传学和分子特征,不同于新发AML。
- 高危细胞遗传学和分子特征频率高,恶性克隆常对传统AML化疗不敏感。
- 异基因干细胞移植是唯一显示长期获益的治疗方式,但常因高龄和合并症无法进行,且复发率仍高。
核心结论
- MPN继发AML的结局总体较差,仍存在显著未被满足的新型治疗策略需求。
- 尽管癌症基因组学进展增进了对MPN克隆演化的理解,但驱动白血病转化的细胞内在和外在机制仍知之甚少。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- MPN继发AML具有独特的细胞遗传学和分子特征,不同于新发AML。
- 高危细胞遗传学和分子特征频率高,恶性克隆常对传统AML化疗药物不敏感。
- 异基因干细胞移植是唯一显示长期获益的治疗方式,但常因诊断时高龄和合并症多而无法进行,且即使移植复发率仍高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary acute myeloid leukemias (AMLs) evolving from an antecedent myeloproliferative neoplasm (MPN) are characterized by a unique set of cytogenetic and molecular features distinct from de novo AML. Given the high frequency of poor-risk cytogenetic and molecular features, malignant clones are frequently insensitive to traditional AML chemotherapeutic agents. Allogeneic stem cell transplant, the only treatment modality shown to have any beneficial long-term outcome, is often not possible given the advanced age of patients at time of diagnosis and frequent presence of competing comorbidities. Even in this setting, relapse rates remain high. As a result, outcomes are generally poor and there remains a significant unmet need for novel therapeutic strategies. Although advances in cancer genomics have dramatically enhanced our understanding of the molecular events governing clonal evolution in MPNs, the cell-intrinsic and -extrinsic mechanisms driving leukemic transformation at this level remain poorly understood. Here, we review known risk factors for the development of leukemic transformation in MPNs, recent progress made in our understanding of the molecular features associated with leukemic transformation, current treatment strategies, and emerging therapeutic options for this high-risk myeloid malignancy.
引用
- Dunbar AJ, Rampal RK, Levine R, et al. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020. PMID: 32430500. doi:10.1182/blood.2019000943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。